INZY - Inozyme Pharma, Inc. Company Long-Term Liabilities

Graphic logo of inozyme.com (INZY)

This daily price chart for Inozyme Pharma, Inc. (INZY) on GURU.Markets, where the indicator stands at 0.02, reflects the quotes of the developer of therapies targeting mineralization anomalies. A lack of competitors allows the firm to exercise pricing power and command premium treatment rates. The unique value of the INZ-701 molecule in treating tissue calcification ensures complete pricing independence. R&D successes and the leadership's authority in metabolism strengthen shareholder confidence.

Company Long-Term Debts: Inozyme Pharma Inc. (INZY) for 07/04/2022 - 07/12/2025

Inozyme Pharma (INZY) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Inozyme Pharma Inc.|INZY - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Inozyme Pharma|INZY - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Inozyme Pharma|INZY - Book Capitalization|Market Capitalization to Book Value Ratio inozyme.com|INZY - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Inozyme Pharma, Inc.|INZY - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Inozyme Pharma Inc.|INZY - Company Total Debt|Debts to Book Capitalization Ratio Inozyme Pharma|INZY - Company Long-Term Debts|Short-Term Debt Inozyme Pharma|Immediate Liquidity Ratio inozyme.com
- company profitability and valuation multiples indicators:
INZY - Net Income
Fundamental company valuation:Inozyme Pharma, Inc., INZY
Manufactured products of Inozyme Pharma, Inc.

Inozyme Pharma, Inc. (INZY) focuses on developing innovative enzyme therapies for the treatment of rare pathologies. Analyzing the company's long-term debt structure, an investor sees a set of obligations with maturities exceeding one year, which determines long-term financial stability. This trend captures the cost of capital servicing during the clinical trial period. For a company without current revenue or pricing power, such debts create a critical dependence on FDA decisions. The stability of this trend confirms the margin of safety for the stock price.

Who Inozyme Pharma, Inc. competes with

vrtx.com (VRTX) - Long-Term Debt|Alnylam - Company Long-Term Debts|Insmed Inc. (INSM) - Company Long-Term Liabilities|UTHR: Company Long-Term Debts|BMRN - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM Group Corp|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Long-Term Debts KROS (Keros Pharma)|Long-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Long-Term Liabilities|Long-Term Liabilities KMDA|FULC: Company Long-Term Debts|Long-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Long-Term Debts|Company Long-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Long-Term Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Long-Term Liabilities|Aytu Therapeutics - Company Long-Term Debts|Company Long-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Long-Term Debts|Polyrizon (PLRZ) - Company Long-Term Debts|Company Long-Term Debt Aeterna Zentaris Inc|CYTH: Company Long-Term Loans and Borrowings|Company Long-Term Debt Reneo Pharma (RPHM)|Company Long-Term Liabilities COSCIENS Bio CSCI